NuCana (NCNA) Competitors

$2.04 0.00 (0.00%)

As of 02:38 PM Eastern

NCNA vs. BCTX, SNTI, LSTA, APLM, and SKYE

Should you buy NuCana stock or one of its competitors? MarketBeat compares NuCana with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NuCana include Briacell Therap (BCTX), Senti Biosciences (SNTI), Lisata Therapeutics (LSTA), Apollomics (APLM), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical products" industry.

How does NuCana compare to Briacell Therap?

NuCana (NASDAQ:NCNA) and Briacell Therap (NASDAQ:BCTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

NuCana is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A

NuCana has a beta of 2.17, indicating that its stock price is 117% more volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

In the previous week, NuCana had 1 more articles in the media than Briacell Therap. MarketBeat recorded 2 mentions for NuCana and 1 mentions for Briacell Therap. NuCana's average media sentiment score of 1.50 beat Briacell Therap's score of 0.00 indicating that NuCana is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NuCana	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NuCana's return on equity of -153.61% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-153.61%	-116.03%
Briacell Therap	N/A	-173.08%	-139.64%

44.0% of NuCana shares are held by institutional investors. Comparatively, 15.4% of Briacell Therap shares are held by institutional investors. 31.2% of NuCana shares are held by insiders. Comparatively, 0.7% of Briacell Therap shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

NuCana beats Briacell Therap on 8 of the 10 factors compared between the two stocks.

How does NuCana compare to Senti Biosciences?

NuCana (NASDAQ:NCNA) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

NuCana has higher earnings, but lower revenue than Senti Biosciences. NuCana is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A
Senti Biosciences	$20K	1,552.83	-$61.44M	-$1.92	N/A

In the previous week, Senti Biosciences had 10 more articles in the media than NuCana. MarketBeat recorded 12 mentions for Senti Biosciences and 2 mentions for NuCana. NuCana's average media sentiment score of 1.50 beat Senti Biosciences' score of -0.12 indicating that NuCana is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NuCana	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Senti Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Senti Biosciences has a consensus target price of $8.75, indicating a potential upside of 777.63%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Senti Biosciences is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

NuCana's return on equity of -153.61% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-153.61%	-116.03%
Senti Biosciences	N/A	-532.05%	-103.35%

NuCana has a beta of 2.17, indicating that its share price is 117% more volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.09, indicating that its share price is 109% more volatile than the broader market.

44.0% of NuCana shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 31.2% of NuCana shares are held by company insiders. Comparatively, 3.1% of Senti Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Senti Biosciences beats NuCana on 9 of the 15 factors compared between the two stocks.

How does NuCana compare to Lisata Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Lisata Therapeutics has higher revenue and earnings than NuCana. Lisata Therapeutics is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	168.54	-$16.59M	-$1.86	N/A
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A

Lisata Therapeutics has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, NuCana has a beta of 2.17, suggesting that its share price is 117% more volatile than the broader market.

In the previous week, Lisata Therapeutics had 2 more articles in the media than NuCana. MarketBeat recorded 4 mentions for Lisata Therapeutics and 2 mentions for NuCana. NuCana's average media sentiment score of 1.50 beat Lisata Therapeutics' score of 0.28 indicating that NuCana is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lisata Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NuCana	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Lisata Therapeutics presently has a consensus target price of $15.00, suggesting a potential upside of 376.95%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Lisata Therapeutics is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 44.0% of NuCana shares are held by institutional investors. 9.6% of Lisata Therapeutics shares are held by company insiders. Comparatively, 31.2% of NuCana shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Lisata Therapeutics' return on equity of -103.54% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
NuCana	N/A	-153.61%	-116.03%

Summary

Lisata Therapeutics beats NuCana on 8 of the 13 factors compared between the two stocks.

How does NuCana compare to Apollomics?

NuCana (NASDAQ:NCNA) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

NuCana has a beta of 2.17, indicating that its share price is 117% more volatile than the broader market. Comparatively, Apollomics has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market.

44.0% of NuCana shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 31.2% of NuCana shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Apollomics' return on equity of 0.00% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-153.61%	-116.03%
Apollomics	N/A	N/A	N/A

Apollomics has higher revenue and earnings than NuCana.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A
Apollomics	$8.50M	3.79	-$10.94M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, NuCana had 2 more articles in the media than Apollomics. MarketBeat recorded 2 mentions for NuCana and 0 mentions for Apollomics. NuCana's average media sentiment score of 1.50 beat Apollomics' score of 0.00 indicating that NuCana is being referred to more favorably in the media.

Company	Overall Sentiment
NuCana	Very Positive
Apollomics	Neutral

Summary

NuCana beats Apollomics on 5 of the 9 factors compared between the two stocks.

How does NuCana compare to Skye Bioscience?

Skye Bioscience (NASDAQ:SKYE) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

NuCana's return on equity of -153.61% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
NuCana	N/A	-153.61%	-116.03%

NuCana is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A

Skye Bioscience has a beta of 3.03, suggesting that its stock price is 203% more volatile than the broader market. Comparatively, NuCana has a beta of 2.17, suggesting that its stock price is 117% more volatile than the broader market.

In the previous week, Skye Bioscience had 1 more articles in the media than NuCana. MarketBeat recorded 3 mentions for Skye Bioscience and 2 mentions for NuCana. NuCana's average media sentiment score of 1.50 beat Skye Bioscience's score of 0.13 indicating that NuCana is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Skye Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NuCana	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Skye Bioscience presently has a consensus price target of $9.80, indicating a potential upside of 1,201.46%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Skye Bioscience is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

21.1% of Skye Bioscience shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 6.2% of Skye Bioscience shares are owned by insiders. Comparatively, 31.2% of NuCana shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Skye Bioscience beats NuCana on 8 of the 14 factors compared between the two stocks.

Get NuCana News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NCNA vs. The Competition

Export

Metric	NuCana	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.49M	$3.35B	$6.33B	$12.33B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	-0.68	18.89	20.88	25.51
Price / Sales	N/A	279.14	520.50	73.06
Price / Cash	N/A	125.35	43.18	55.00
Price / Book	0.28	6.90	10.01	7.03
Net Income	-$38.71M	$24.18M	$3.54B	$334.92M
7 Day Performance	3.03%	0.77%	0.38%	-0.40%
1 Month Performance	-5.99%	-0.38%	-0.02%	1.07%
1 Year Performance	-74.75%	63.37%	35.07%	34.65%

NuCana Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NCNA NuCana	0.7526 of 5 stars	$2.04 flat	N/A	-78.0%	$8.49M	N/A	N/A	30	Positive News Earnings Report Gap Up
BCTX Briacell Therap	0.1789 of 5 stars	$4.05 -3.1%	N/A	-89.1%	$30.31M	N/A	N/A	8
SNTI Senti Biosciences	2.3525 of 5 stars	$1.04 +8.0%	$8.50 +717.3%	-69.4%	$29.99M	$20K	N/A	4	Earnings Report Analyst Revision Gap Up High Trading Volume
LSTA Lisata Therapeutics	1.9837 of 5 stars	$3.08 -6.1%	$15.00 +387.0%	+24.7%	$29.87M	$170K	N/A	30	Positive News Analyst Upgrade Analyst Revision
APLM Apollomics	0.8174 of 5 stars	$13.92 +2.9%	N/A	+154.2%	$29.71M	$8.50M	N/A	45	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NCNA) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NuCana (NCNA) Competitors

NCNA vs. BCTX, SNTI, LSTA, APLM, and SKYE

How does NuCana compare to Briacell Therap?

Summary

How does NuCana compare to Senti Biosciences?

Summary

How does NuCana compare to Lisata Therapeutics?

Summary

How does NuCana compare to Apollomics?

Summary

How does NuCana compare to Skye Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCNA vs. The Competition

NuCana Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NuCana (NCNA) Competitors

NCNA vs. BCTX, SNTI, LSTA, APLM, and SKYE

How does NuCana compare to Briacell Therap?

Which has stronger earnings and valuation, NCNA or BCTX?

Which has more volatility & risk, NCNA or BCTX?

Does the media prefer NCNA or BCTX?

Do analysts recommend NCNA or BCTX?

Is NCNA or BCTX more profitable?

Do institutionals & insiders believe in NCNA or BCTX?

Summary

How does NuCana compare to Senti Biosciences?

Which has better earnings & valuation, NCNA or SNTI?

Does the media prefer NCNA or SNTI?

Do analysts prefer NCNA or SNTI?

Is NCNA or SNTI more profitable?

Which has more volatility and risk, NCNA or SNTI?

Do insiders & institutionals believe in NCNA or SNTI?

Summary

How does NuCana compare to Lisata Therapeutics?

Which has better earnings and valuation, LSTA or NCNA?

Which has more risk & volatility, LSTA or NCNA?

Does the media favor LSTA or NCNA?

Do analysts prefer LSTA or NCNA?

Do insiders and institutionals hold more shares of LSTA or NCNA?

Is LSTA or NCNA more profitable?

Summary

How does NuCana compare to Apollomics?

Which has more volatility and risk, NCNA or APLM?

Do insiders & institutionals have more ownership in NCNA or APLM?

Is NCNA or APLM more profitable?

Which has preferable earnings & valuation, NCNA or APLM?

Do analysts recommend NCNA or APLM?

Does the media refer more to NCNA or APLM?

Summary

How does NuCana compare to Skye Bioscience?

Is SKYE or NCNA more profitable?

Which has stronger earnings and valuation, SKYE or NCNA?

Which has more volatility and risk, SKYE or NCNA?

Does the media refer more to SKYE or NCNA?

Do analysts rate SKYE or NCNA?

Do insiders and institutionals have more ownership in SKYE or NCNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCNA vs. The Competition

NuCana Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools